Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
What can the molecular pathologist offer for optimal decision making?Richman SD; Hutchins GG; Seymour MT; Quirke PAnn Oncol 2010[Oct]; 21 Suppl 7 (ä): vii123-9As a consequence of new innovative therapies and therapeutic combinations, the treatment of advanced colorectal cancer is becoming increasingly complex. Validated molecular biomarkers could contribute to patient management, but until recently, none has been routinely used. With the recognition that activating mutations of the KRAS oncogene can predict resistance to anti-epidermal growth factor receptor agents, the clinical value of biomarkers in advanced colorectal cancer has been brought to the fore. Prognostic and predictive biomarkers that reflect the molecular and therapeutic complexities of advanced colorectal cancer may provide valuable information regarding likely clinical outcome and therapeutic response and thus may improve patient management and therapeutic agent selection. Such biomarkers are discussed herein.|*Decision Making/physiology[MESH]|Biomarkers, Tumor/analysis/genetics[MESH]|Carcinoma/diagnosis/genetics/pathology/*therapy[MESH]|Colorectal Neoplasms/diagnosis/genetics/pathology/*therapy[MESH]|Drug Resistance, Neoplasm/genetics[MESH]|Humans[MESH]|Pathology, Molecular/*methods[MESH]|Prognosis[MESH]|Proto-Oncogene Proteins p21(ras)[MESH]|Proto-Oncogene Proteins/genetics[MESH]|ras Proteins/genetics[MESH] |
